Poseidon: Durvalumab +/- Tremelimumab + Chemo In 1L Mnsclc

POSEIDON: durvalumab +/- tremelimumab + chemo in 1L mNSCLC

POSEIDON: 4 year follow up of durvalumab and tremelimumab in NSCLC

ASCO 2021 Lung Recap: Poseidon Trial: Durvalumab +/- Tremelimumab vs. Chemo Alone

GRACE - Global Resource for Advancing Cancer Education

A Study of Chemotherapy With Durvalumab and Tremelimumab in NSCLC

Targeted Oncology

Four chemo cycles given with durvalumab ± tremelimumab optimise response in patients with mNSCLC

DUTRENEO: durvalumab and tremelimumab vs chemo

Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC

Dr. Balar on Impact of Durvalumab Plus Tremelimumab in Bladder Cancer

Tremelimumab and durvalumab therapy in lung cancer

Stage III NSCLC: When to Start Durvalumab

Abstract 1220: Association Between KRAS/STK11/KEAP1 Mutations & Outcomes in POSEIDON: Durva ± Tr...

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC

Immune checkpoint inhibitors, durvalumab plus tremelimumab, for non-small cell lung cancer

EMJ

DANUBE trial: Durvalumab alone or with tremelimumab for metastatic bladder cancer

Medicine Matters oncology

Updated results from the CASPIAN trial of durvalumab plus chemo in SCLC

PACIFIC trial updates: durvalumab after chemotherapy in NSCLC

[lung]The role of durvalumab in patients with stage 3 lung cancer in a real hospital

David Lauren Research | Oncology in 3 minutes.

ILLUMINATE: Durvalumab, Tremelimumab, and Chemotherapy in EGFR Mutant NSCLC | Dr. Ankur Punia| CRSF

CRSF - Cancer Research and Statistic Foundation

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for ch...